Skoltech researchers and their colleagues have synthesized and tested protein-polymer microbubbles for use in medical ultrasound imaging of internal organs. Administered intravenously, the ...

A research team at POSTECH (Pohang University of Science and Technology) has investigated kidney diseases using ultrafast ultrasound that captures 1,000 images in just one second. The research team ...

CHICAGO--(BUSINESS WIRE)--Ultrasound contrast agents show promise for detecting and evaluating uterine disorders and prostate cancers, scientists reported today at the annual Advances in Contrast ...

Impaired mucociliary transport is a distinguishing sign of cystic fibrosis, but current methods of evaluation are invasive or expose young patients to ionizing radiation. Contrast-enhanced ultrasound ...

CHICAGO--(BUSINESS WIRE)--Ultrasound experts today urged the health care community to work to expand utilization of ultrasound contrast agents (UCAs) in order to offer patients broader access to ...

A new contrast agent could allow real-time monitoring of pH changes in the body using an ultrasound scanner (ACS Sens. 2020, DOI: 10.1021/acssensors.0c00245). This expansion of the use of ultrasound ...

Primary liver cancer is the third cause of cancer death worldwide with 906,000 new cases and 830,000 deaths. Of these, 75-85% of patients are hepatocellular carcinoma (HCC), while the remaining 15-25% ...

Type 1 diabetes (T1D) is caused by infiltration of auto-reactive T-cells into the pancreatic islets and the destruction of the insulin-producing β-cells 1. Prior to the clinical presentation of ...

The USphere Series of microbubble contrast agents has been carefully designed for preclinical imaging, operating efficiently at frequencies ranging from 1 to 40 MHz. Their small size distribution (1.1 ...

Co-leaders of Case CCC's Cancer Imaging Program, Agata Exner, PhD (PI) and James Basilion, PhD (MPI) received a four-year, $2.4M NIH grant to continue the development, implementation, and clinical ...

Implication of DYRK1B kinase in dormant glioblastoma cancers and utilization of DYRK1B inhibitors as a novel therapeutic strategy for glioblastoma. This is an ASCO Meeting Abstract from the 2019 ASCO ...

Primary liver cancer is the third cause of cancer death worldwide, with 906,000 new cases and 830,000 deaths. Of these, 75-85% of patients are hepatocellular carcinoma (HCC), while the remaining 15-25 ...